The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Memorandum of Understanding with AbbVie and M42 for collaborative efforts in tailoring personalized medicine and genomics in Abu Dhabi. M42 is a tech-enabled, integrated healthcare company comprised of G42 Healthcare and Mubadala Health.
 
The three parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. DoH aims to drive research that will contribute to policy changes and guideline implementation which will enable broader patient access to innovative approaches in healthcare.

As part of its preventive healthcare efforts, Abu Dhabi launched the region’s first Personalized Precision Medicine Program for oncology in 2022. The program integrates predictive, personalized and precision medicine using genomics to transform diagnostics, drug therapy and prevention and tailor it to the needs specific to individuals.
 
Hassan Sabbah, General Manager AbbVie Gulf & Levant said: “This partnership aims to advance precision medicine in the diagnosis and treatment to help enable broader patient access in UAE to innovative therapies. Our efforts are progressing to launch several initiatives that support research and clinical trials and develop innovative solutions to deal effectively with local and regional health needs, challenges, and burdens.”
 
Francesco Redivo, Senior Director at G42 Healthcare, a M42 company said: “I am proud to witness how our vision of realizing personalized healthcare is progressing forward. Our collaboration will be built on joint efforts to advance precision medicine by harnessing real world evidence capabilities, shaping innovative solutions around access to care and translating scientific advancements into tangible patient benefits by maximizing the potential of Emirati Genome Program.”